1. Long-term Response of Helicobacter pylori Antibody Titer After Eradication Treatment in Middle-aged Japanese: JPHC-NEXT Study
- Author
-
Kiyoshi Aoyagi, Kozo Tanno, Shoichiro Tsugane, Kiyomi Sakata, Nobufumi Yasuda, Isao Saito, Taichi Shimazu, Tadahiro Kato, Isao Muraki, Hiroyasu Iso, Taiki Yamaji, Kazumasa Yamagishi, Motoki Iwasaki, Shiori Tanaka, Atsushi Goto, Kazuhiko Arima, Norie Sawada, and Manami Inoue
- Subjects
medicine.medical_specialty ,biology ,Epidemiology ,business.industry ,Antibody titer ,030209 endocrinology & metabolism ,General Medicine ,Helicobacter pylori ,biology.organism_classification ,Gastroenterology ,Serology ,03 medical and health sciences ,Titer ,0302 clinical medicine ,Internal medicine ,Cohort ,biology.protein ,medicine ,Population study ,030212 general & internal medicine ,Antibody ,business ,Prospective cohort study - Abstract
BACKGROUND Helicobacter pylori (H. pylori) is an established causative factor of gastric cancer. Although the expansion of insurance coverage has led to an increase in the number of patients treated for H. pylori, the population impact of eradication treatment for H.pylori has been scarcely investigated. This study aimed to clarify the long-term responses of H. pylori antibody titer after eradication treatment using large scale cross-sectional data from the Japan Public Health Center-based Prospective Study for the Next Generation (JPHC-NEXT Study). METHODS A total of 55,282 Japanese participants aged 40 to 74 years residing in 16 areas provided blood samples between 2011 and 2016. From these, treated (n=6,276) and untreated subjects who were seropositive for H. pylori or had serological atrophy (n= 22,420) formed the study population (n=28,696). Seropositivity was defined as an anti-H. pylori IgG titer of ≥10 U/mL. Antibody level was compared among subjects according to self-reported treatment history as untreated, and treated for less than one year (
- Published
- 2023